Certara, Paidion Research Form Pediatric Drug Partnership

Published on: 

Applied Clinical Trials

Certara® and Paidion Research, announced a new partnership to address the challenges inherent in pediatric drug development.

Certara®, a global biosimulation technology-enabled drug development company, and Paidion Research, a pediatric clinical research organization (CRO), announced a new partnership to address the challenges inherent in pediatric drug development including safe and effective dose or dose ranges and the conduct of trials. The partnership joins together Certara’s Simcyp® Pediatric PBPK simulator to inform the dose selections, with Paidon’s neonatal and pediatric intensive care unit and pediatric clinical site networks and clinical trials experience.

 

Advertisement

Read the full release here.